Cognigenics: Pioneering the frontier of RNA-based therapeutics for mental health and neurodegeneration.
At Cognigenics, we are pioneering new approaches to treating mental health disorders and neurodegenerative diseases. Our cutting-edge, patent-pending technology employs genetic neuroengineering techniques to accurately and noninvasively target the neural networks implicated in conditions such as anxiety, depression, cognitive decline and memory.
Leveraging the precise application of short hairpin RNA (shRNA)-based therapeutics, our technology mitigates the harmful consequences of chronic stress and disorders arising from chronic neural dysregulation, including (but not not limited to) Anxiety Spectrum Disorders (ASD), Mild Cognitive Impairment (MCI), and Alzheimer’s Disease (AD).
Our RNA-based therapeutic approaches are developed to support long-term cognitive health by improving functions such as focus, attention, and mental clarity, as well as fostering a sense of relaxation and optimism. These treatments are engineered with molecular precision to address specific pathophysiological aspects of mental health disorders and neurodegenerative diseases. Our preclinical studies suggest that our interventions may have the potential to yield high efficacy rates in symptom management with a favorable safety profile, significantly reducing the burden of these conditions